Loading
A phase 1/2 trial of trametinib in colorectal cancer, run by Xynomic Pharmaceuticals, Inc., not yet recruiting.
XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation is a phase 1/2, interventional study registered as NCT05275374 by Xynomic Pharmaceuticals, Inc., with a registry enrolment figure of 221 participants, started 2025-12-31 and due to reach its primary completion in 2027-12-30. Interventions recorded: XP-102; Trametinib. Conditions listed: Cancer; BRAF V600 Mutation; Melanoma; Colorectal Cancer; Thyroid Cancer; Nonsmall Cell Lung Cancer. Primary outcome: Characterize the safety of XP-102.; Evaluate the pharmacokinetics of XP-102.; Establish maximum tolerated dose of XP-102.. Colorectal eligibility wording from the registry: "* Advanced malignant solid tumor patients with a BRAF V600 mutation (limited to melanoma, colorectal cancer, non-small cell lung cancer, or thyroid cancer)". No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares BRAF V600E-mutant colorectal cancer, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares BRAF V600E-mutant colorectal cancer, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares BRAF V600E-mutant colorectal cancer, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares BRAF V600E-mutant colorectal cancer, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares BRAF V600E-mutant colorectal cancer, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares BRAF V600E-mutant colorectal cancer, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares BRAF V600E-mutant colorectal cancer, Colorectal cancer trials open today (registry snapshot), Rectal cancer, Small-molecule kinase inhibitors and the tag colorectal-deep-dive.
Shares BRAF V600E-mutant colorectal cancer, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/